meningococcal group C conjugate vaccine + pneumococcal conjugate vaccine

This entry refers to the co-administration of Meningococcal Group C (MenC) conjugate vaccines and Pneumococcal Conjugate Vaccines (PCV) within pediatric immunization schedules. Public Health England (formerly the Health Protection Agency) conducted Phase 4 clinical research to evaluate the immunogenicity and safety of reduced primary dosing schedules (e.g., two doses instead of three) for these vaccines in infants. MenC vaccines utilize purified capsular polysaccharides from Neisseria meningitidis serogroup C conjugated to carrier proteins such as CRM197 or tetanus toxoid to elicit a robust, T-cell dependent immune response in young children. Similarly, PCVs (such as PCV7 or PCV13) contain polysaccharides from multiple Streptococcus pneumoniae serotypes conjugated to a carrier protein to prevent invasive pneumococcal disease. The co-administration of these vaccines is a standard practice in many national immunization programs to provide broad protection against bacterial meningitis and pneumonia.

Brand names

MenjugateNeisVac-CMeningitecPrevenarPrevnar

Other names

MenC + PCVMeningococcal C and Pneumococcal Conjugate Vaccines